This involves a negative pregnancy test before starting treatment, use of highly effective contraception throughout (noting that topiramate may reduce the efficacy of some combined hormonal contraceptives discuss suitable methods with your prescriber), and annual counselling with completion of a Risk Acknowledgement Form
Eligibility and approval are always at the discretion of the prescriber, who will determine eligibility based on an assessment of your complete health profile
Therefore, SUSTAIN 6 showed that the effects of semaglutide on the primary composite endpoint were not affected by renal subgroup [23]
Keywords: GLP-1 receptor agonist, polycystic ovary syndrome, semaglutide, inflammation Introduction Polycystic ovary syndrome (PCOS), a common reproductive endocrine disease, affects approximately 610% of young women.1 Infrequent menstruation, ovulation disorders, hyperandrogenemia (HA), polycystic ovarian changes, and insulin resistance (IR) are the main characteristics of PCOS.2 The etiology of PCOS is complex, including hypothalamic and ovarian dysfunction, chronic inflammation, IR, obesity related mechanisms, and excessive exposure to androgens.3,4 Currently, diet adjustment, exercise intervention, and medication are the main treatment methods for PCOS